Associated with several familial cancers, including breast cancer, ovarian cancer, and prostate cancer. The cumulative lifetime risk of breast cancer for women who carry mutations in BRCA1 is approximately 92%, while the cumulative lifetime risk for noncarriers is estimated to be 10%. BRCA1 and BRCA2 participate together in a pathway (or pathways) associated with the activation of double-strand break repair and/or homologous recombination.
BRCA1 antibody can be used in ELISA, Western Blot, and immunohistochemistry starting at 5 μg/mL.
PBS, 0.02% sodium azide, 50% glycerol.
Aliquot and store at -80°C. Avoid multiple freeze-thaw cycles.